Literature DB >> 24030749

Nestin expression is associated with aggressive cutaneous melanoma of the nodular type.

Rita G Ladstein1, Ingeborg M Bachmann2, Oddbjørn Straume3, Lars A Akslen4.   

Abstract

The intermediate filament nestin, a neural stem-cell marker, is reported to be expressed more strongly in melanomas compared with benign melanocytic lesions, and increasingly expressed in advanced melanoma stages. However, the prognostic impact of nestin on melanoma has not been well elucidated. The aim of the present study was to evaluate the prognostic influence of nestin expression in cutaneous melanoma in comparison with standard clinico-pathologic variables. In a large series of nodular cutaneous melanoma (n=348), nestin expression was assessed by immunohistochemistry using tissue microarray (TMA) sections. For comparison, nestin staining in corresponding metastases as well as in superficial spreading melanomas and benign nevi was also examined. Nestin was expressed to varying degrees in a majority of nodular melanomas (92%), and was significantly associated with increased tumor thickness, high mitotic count, and the presence of ulceration and tumor necrosis. Also, expression was stronger in the nodular type than in superficial spreading melanomas and benign nevi, but without significant difference when compared with matched metastases from the former. Importantly, strong expression of nestin was significantly associated with reduced survival in multivariate analysis. In conclusion, increased nestin expression was associated with aggressive melanoma features, with independent prognostic impact on multivariate survival analysis when compared with clinico-pathologic factors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24030749     DOI: 10.1038/modpathol.2013.151

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

Review 1.  No one should die of melanoma: a vision or impossible mission?

Authors:  Iris Zalaudek; Elvira Moscarella; Caterina Longo; Aimilios Lallas; Giuseppe Argenziano; Rainer Hofmann-Wellenhof
Journal:  Melanoma Manag       Date:  2014-09-05

2.  RNAi-mediated human Nestin silence inhibits proliferation and migration of malignant melanoma cells by G1/S arrest via Akt-GSK3β-Rb pathway.

Authors:  Xu-Hui Yang; Tian Xia; Jie Zhang; Shao-Fen Yang; Hui-Xia Tang; Ting Tang; Zhi-Cheng Huang; Yue-Si Zhong; Feng He; Andy Peng Xiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

3.  BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors.

Authors:  Deon B Doxie; Allison R Greenplate; Jocelyn S Gandelman; Kirsten E Diggins; Caroline E Roe; Kimberly B Dahlman; Jeffrey A Sosman; Mark C Kelley; Jonathan M Irish
Journal:  Pigment Cell Melanoma Res       Date:  2018-06-28       Impact factor: 4.693

4.  RNA interference-mediated knockdown of SIRT1 and/or SIRT2 in melanoma: Identification of downstream targets by large-scale proteomics analysis.

Authors:  Melissa J Wilking-Busch; Mary A Ndiaye; Xiaoqi Liu; Nihal Ahmad
Journal:  J Proteomics       Date:  2017-09-05       Impact factor: 4.044

5.  Clinicopathological characteristics of malignant melanomas of the skin and gastrointestinal tract.

Authors:  Michiko Akiyama; Yoko Matsuda; Tomio Arai; Hidehisa Saeki
Journal:  Oncol Lett       Date:  2018-06-06       Impact factor: 2.967

6.  Classification and Grading of Melanocytic Lesions in a Mouse Model of NRAS-driven Melanomagenesis.

Authors:  Charles-Antoine Assenmacher; Sara F Santagostino; Mark A Oyama; Jean-Christophe Marine; Elise Bonvin; Enrico Radaelli
Journal:  J Histochem Cytochem       Date:  2020-12-07       Impact factor: 2.479

7.  Clinicopathological and prognostic significance of nestin expression in patients with breast cancer: a systematic review and meta-analysis.

Authors:  Xinyi Zhang; Changsheng Xing; Wenting Guan; Lang Chen; Kai Guo; Anze Yu; Kai Xie
Journal:  Cancer Cell Int       Date:  2020-05-14       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.